metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA) 1
es-BC - HER2 positive - (neo)adjuvant (NA) 4
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1) 5
la/mBC - HER2 positive - 2nd Line (L2) 13

All treatments
antibody–drug conjugate
trastuzumab deruxtecan
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib plus vinorelbine
HER2 inhibitor
neratinib based treatment
neratinib
neratinib plus capecitabine
pertuzumab based treatment
pertuzumab plus trastuzumab
pertuzumab plus trastuzumab plus docetaxel
trastuzumab based treatment
trastuzumab plus endocrine therapy
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib
lapatinib plus capecitabine
lapatinib plus trastuzumab
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
inetetamab plus vinorelbine
target therapy
margetuximab based treatment
margetuximab plus chemotherapy
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab plus trastuzumab plus docetaxel

versus all
vs antibody–drug conjugate
vs trastuzumab emtansine
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs paclitaxel followed by doxorubicin plus cyclophosphamide
vs vinca alkaloids
vs vinorelbine
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus capecitabine
vs trastuzumab plus chemotherapy
vs trastuzumab plus docetaxel
vs trastuzumab plus endocrine therapy
vs trastuzumab plus vinorelbine
vs TKI anti HER1/EGFR and HER2/neu
vs lapatinib based treatment
vs lapatinib
vs lapatinib plus capecitabine
vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open